X

Trial Profile

A Phase II Trial of Combination Bortezomib and Rituximab as Front-Line Therapy for Low-Grade Non-Hodgkin's Lymphoma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Sep 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Rituximab (Primary)
Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
Focus Therapeutic Use

Most Recent Events

22 Oct 2018 Status changed from active, no longer recruiting to completed.
19 Oct 2016 Planned End Date changed from 1 Aug 2017 to 1 Aug 2019.
19 Oct 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com